Shares of Hims & Hers Health plunged Friday after the Food & Drug Administration said a shortage of the active ingredient in ...

The ruling shows Novo Nordisk’s confidence that the supply of semaglutide will be stable for now.

Compounding pharmacies producing cheaper semaglutide products have been given notice they will soon have to stop, as the drug ...

Hims & Hers Health (HIMS) stock falls as the FDA declares that Novo Nordisk's (NVO) weight loss therapies are no longer in ...

Semaglutide is a glucagon-like peptide-1 (GLP-1) that helps regulate blood sugar levels. Because of outsized demand for ...

Shares of Hims & Hers Health ( HIMS -25.79%) are falling on Friday. The company's stock lost 23.2% as of 1 p.m. ET and lost ...

Hims & Hers Health (NYSE:HIMS) is set to report its earnings on Monday, Feb 24 after market close. HIMS stock plunged over 25 ...

The FDA has now resolved the shortages of Novo Nordisk’s and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...

The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk's popular weight-loss and ...

We will continue to offer access to personalized treatments as allowed by law to meet patient needs,” Hims & Hers CEO said.

Ozempic and Wegovy, the widely popular forms of semaglutide sold to treat diabetes and obesity, have officially been removed ...

Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and ...